A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study
Bone Marrow Transplantation · 2025
DOI: 10.1038/s41409-024-02480-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Bone Marrow Transplantation, 2025. Verfasst von Jian-Ying Zhou und 38 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myelomonocytic, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy and the only curable therapy is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, allo-HSCT is not appropriate for all CMML patients, and relapse is the leading cause of treatment failure. This project conducted a nationwide multicenter real-world study to develop a novel prediction scoring system for early relapse. A total of 238 CMML patients from twenty-seven medical centers treated with allo-HSCT, and 307 adult patients with CMML who underwent allo-HSCT in a publicly available research dataset from the Center for International Blood and Marrow Transplantation Registry (CIBMTR) database were included. Independent prognostic factors for the early relapse of CMML posttransplantation were identified according to competing risk regression methods. Four prognostic factors were identified: bone marrow blasts >10% (hazard ratio [HR], 4.262; P = 0.014), age >60 years (HR, 6.221; P = 0.007), hemoglobin level 2 points) groups. The validated internal c-statistic was 0.767 (95% confidence interval [CI], 0.674-0.860), and the external c-statistic was 0.769 (95% CI, 0.703-0.836). In the derivation cohort, the cumulative incidence rates of early relapse in the low-risk, intermediate-risk, and high-risk groups were 1.35% (95% CI: 1-4%), 10.40% (95% CI: 4-16%), and 29.54% (95% CI: 16-39%) (P < 0.001), respectively. This scoring system can be utilized to early identification of patients at a high risk of relapse and contributing to the implementation of urgent medical support.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
- Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
- Department of Hematology, Xiangya Hospital of Central South University, Changsha, China.
- Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Hematology section, Cancer Center, The First Hospital of Jilin University, Changchun, China.
- Department of Hematology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Xiao-Bing Huang, Yi Luo, Yu-Hua Li, Xi Zhang, Zun-Min Zhu, Hai Yi, Xiang-Yu Zhao, Xiao-Jun Huang, Xiao-Hui Zhang
Förderung
- NCI NIH HHS
Zitieren
APA
Zhou, J. Y., Chen, Y. X., Yuan, H. L., Xu, Y. J., Huang, X. B., Gao, S. J., Zhang, Y. C., Zhou, F., Song, X. M., Luo, Y., Yang, J. M., Li, Y. H., Wang, S. Q., Dong, Y. J., Zhang, X., Feng, Y. M., Du, X., Zhu, H., Zhu, Z. M., …, & Zhang, X. H. (2025). A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02480-3
Vancouver
Zhou JY, Chen YX, Yuan HL, Xu YJ, Huang XB, Gao SJ, et al. A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study. Bone Marrow Transplantation. 2025. doi:10.1038/s41409-024-02480-3
BibTeX
@article{Zhou2025,
author = {Zhou, Jian-Ying and Chen, Yu-Xiu and Yuan, Hai-Long and Xu, Ya-Jing and Huang, Xiao-Bing and Gao, Su-Jun and Zhang, Yi-Cheng and Zhou, Fang and Song, Xian-Min and Luo, Yi and Yang, Jian-Min and Li, Yu-Hua and Wang, Shun-Qing and Dong, Yu-Jun and Zhang, Xi and Feng, Yi-Mei and Du, Xin and Zhu, Han and Zhu, Zun-Min and Bi, Ke-Hong and Jiang, Ming and Niu, Ting and Wan, Ding-Ming and Chen, Yi and Liu, Li and Yi, Hai and Chen, Yu-Hong and Wang, Feng-Rong and Zhang, Yuan-Yuan and Mo, Xiao-Dong and Han, Wei and Wang, Jing-Zhi and Wang, Yu and Chen, Huan and Zhao, Xiang-Yu and Chang, Ying-Jun and Liu, Kai-Yan and Huang, Xiao-Jun and Zhang, Xiao-Hui},
title = {A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study},
journal = {Bone Marrow Transplantation},
year = {2025},
doi = {10.1038/s41409-024-02480-3}
}
EUVIMED